arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

TEVA PHARMACEUTICAL INDUSTRIES LTD

TEVA
$35.35 ▲ +0.54 (+1.55%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
45 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Bullish
auto_awesome

Analytical Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $41.2B
Dividend Yield
Revenue Growth -0.8%
Op. Margin -5.6%
ROIC -2.4%
FCF / Share $0.35
Trailing P/E
Price / Book 5.3x
FCF Yield 1.0%
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

45-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$4.14B
↓ -0.8%
Net Income Profit after all expenses
$-576.00M
↓ -256.1%
Operating Margin Operating profit as % of sales
-5.6%
↓ -134.1% 62th
FCF / Share Free cash flow per share
$0.35
↑ +78.3%
Long-Term Debt Long-term obligations
$32.52B
↑ +701.5%
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
60
Returns
84
Financial Health
62
Cash Quality
72

Dividend History

Dividend / share · sourced from SEC filings
$0.00 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 16 years · 45 quarters